Q (sonnet): list the portal studies for pediatric cancers that were published in the last 5 years

▶ list_studies
{
 "search": "pediatric",
 "limit": 100,
 "verbose": true
}

◀ result
{"result":[{"cancer_study_identifier":"all_phase2_target_2018_pub","name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 298 Pediatric Acute Lymphoid Leukemia - Phase II samples. Comprehensive profiling of ALL Phase 2 samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p","type_of_cancer_id":"bll","sample_count":1978,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=all_phase2_target_2018_pub"},{"cancer_study_identifier":"nbl_target_2018_pub","name":"Pediatric Neuroblastoma (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 1089 NBL samples. Comprehensive profiling of 1089 NBL samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p>","type_of_cancer_id":"nbl","sample_count":1089,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=nbl_target_2018_pub"},{"cancer_study_identifier":"aml_target_2018_pub","name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 333 TARGET-AML samples. Comprehensive profiling of TARGET-AML samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnost … (9828 more chars)

═ answer (success)
Filtering to studies with publication years 2021–2026 (based on study identifiers/names), here are the pediatric cancer studies published in the last 5 years:

| Study | Study ID | Publication | Samples |
|---|---|---|---|
| Pediatric Acute Myeloid Leukemia | `aml_stjude_2024` | St. Jude, *Nat Genet* 2024 | 887 |
| Pediatric European MAPPYACTS Trial | `pancan_mappyacts_2022` | Gustave Roussy, *Cancer Discov* 2022 | 786 |
| Pediatric Neuroblastoma | `nbl_msk_2023` | MSK, *Nat Genet* 2023 | 223 |
| Pediatric Brain Cancer | `brain_cptac_2020` | CPTAC/CHOP, *Cell* 2020 | 218 |
| Pediatric solid tumor PDXs | `pancan_pdx_uthsa_2023` | UTHSA, *Nat Commun* 2023 | 136 |
| Pediatric Pancan Tumors | `mixed_kunga_msk_2022` | MSK, *Nat Commun* 2022 | 135 |
| Pediatric Tumors (MAI program) | `pancan_ped_mai_msk_2025` | MSK, 2025 | 60 |
| Pediatric Low-Grade Glioma | `lgg_ctf_synodos_2025` | CTF, *Acta Neuropathol* 2021 (reprocessed 2025) | 31 |
| Pediatric Rhabdomyosarcomas | `rms_msk_2023` | MSK, *JCO Precis Oncol* 2023 | 24 |

Note: `brain_cptac_2020` (published 2020) is right at the boundary of the 5-year window (2021–2026); included for completeness. Excluded older studies: TARGET cohorts (2018), DKFZ Pan-Cancer (2017), PPTC (2019), Ewing Sarcoma (2014), Columbia pan-cancer (2016), and Medulloblastoma PCGP (2012).

Would you like me to open the Study View for any of these cohorts, or generate a cross-study comparison (e.g., mutation frequency across all of them)?